Share This Page
Suppliers and packagers for ORBACTIV
✉ Email this page to a colleague
ORBACTIV
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Melinta Therap | ORBACTIV | oritavancin diphosphate | POWDER;INTRAVENOUS | 206334 | NDA | Melinta Therapeutics, LLC | 70842-140-03 | 3 VIAL, GLASS in 1 CARTON (70842-140-03) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, GLASS (70842-140-01) | 2014-09-01 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Orbactiv
Introduction
Orbactiv (oritavancin) is a long-acting lipoglycopeptide antibiotic approved by the U.S. Food and Drug Administration (FDA) for the treatment of complicated skin and skin structure infections (cSSSI) caused by susceptible bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). As a critical treatment option within its therapeutic niche, understanding its supply chain dynamics is essential for healthcare providers, pharmaceutical distributors, and stakeholders involved in its manufacturing and distribution.
This analysis details the key suppliers involved in the production of Orbactiv, examining manufacturing sources, distribution networks, and recent supply chain trends impacting availability. The focus remains on providing actionable insights for decision-makers in healthcare procurement and pharmaceutical supply chain management.
Manufacturers of Oritavancin (Orbactiv)
1. Melinta Therapeutics
Originally, Orbactiv was developed and marketed by Melinta Therapeutics, a biopharmaceutical company headquartered in the United States. Melinta held exclusive rights to manufacture and distribute oritavancin, making it the primary supplier's source of the drug. The company's manufacturing processes follow strict FDA Good Manufacturing Practices (GMP) protocols, ensuring quality and regulatory compliance.
In 2022, Melinta announced strategic changes, including restructuring efforts due to financial pressures, which impacted production stability. Despite these challenges, Melinta was the sole authorized commercial manufacturer of Orbactiv within the United States, supplying hospitals and healthcare facilities across North America.
2. Contract Manufacturing Organizations (CMOs)
Given the specialized nature of oritavancin synthesis—requiring complex chemical synthesis, purification, and formulation—Melinta has engaged third-party CMOs to support manufacturing needs. These CMOs are responsible for scaling production capacity, ensuring continuity, and maintaining quality standards. Names of these CMOs are generally confidential due to proprietary and regulatory reasons, but industry sources suggest partnerships with contract manufacturers based in Europe and Asia.
Engagement with CMOs enables Melinta to expand manufacturing capacity or mitigate risks related to supply disruptions, especially considering the complex synthesis pathway and stringent regulatory oversight typical of antibiotic production.
Global Supply Chain and Distribution Networks
1. Distribution Partners
After manufacturing, Orbactiv passes through broad distribution networks managed by Melinta's distribution partners. The primary distribution channels include:
-
Pharmaceutical Distributors: Major distributors such as McKesson, Cardinal Health, and AmerisourceBerrry’s logistics subsidiaries stock Orbactiv and supply hospitals, clinics, and specialty pharmacies.
-
Specialty Pharmacy Networks: Given its use in hospital settings, Orbactiv is often supplied directly to specialty pharmacies and infusion centers, which facilitate outpatient administration.
-
Import/Export Dynamics: Although primarily supplied within the U.S., some quantities are exported through regulated channels to select global markets. This is subject to regulatory approval and licensing agreements.
2. Supply Chain Challenges
Recently, the supply of Orbactiv has faced challenges, including manufacturing delays, disruptions caused by geopolitical factors such as supply chain constraints linked to COVID-19, and manufacturing capacity limitations. Melinta’s financial instability has also resulted in temporary shortages or limited distribution in some regions, prompting healthcare facilities to explore alternative antibiotics with comparable efficacy.
3. Regulatory and Market Impact
The exclusivity of Melinta’s manufacturing rights, combined with complex patent protections, limits the entry of generic competitors. However, the manufacturing complexity and recent supply constraints underscore the importance of diversified sourcing strategies and early planning to mitigate shortages.
Emerging Trends and the Future of Supply
1. Potential for Biosimilars and Generics
Given the clinical importance of oritavancin, regulatory bodies and manufacturers are exploring the pathway for biosimilar or generic versions. However, as of 2023, no approved biosimilars or generics specifically targeting oritavancin are commercially available. The high complexity of manufacturing and patent protections present barriers to market entry but also serve as incentives for new entrants.
2. Strategic Stockpiling and Supply Chain Resilience
Healthcare providers increasingly prioritize supply chain resilience. Strategic stockpiling and diversified sourcing are becoming best practices, especially for critical antibiotics like Orbactiv. Companies are investing in expanding manufacturing capacities and establishing international manufacturing partnerships to reduce dependence on single sources.
3. Innovations in Manufacturing Technologies
Advances in synthetic chemistry, process automation, and quality control are poised to enhance production efficiencies. This evolution may lead to increased supply stability and possibly facilitate the entry of generic manufacturers in the future, pending patent expirations and regulatory approvals.
Impact on Healthcare Stakeholders
The limited number of suppliers primarily centered on Melinta’s manufacturing capabilities means supply disruptions can significantly impact patient access. Hospitals and clinicians must monitor supply levels regularly, engage with distributors for contingency planning, and consider alternative therapies if necessary.
Furthermore, the development of new oritavancin biosimilars or generics could disrupt current supply dynamics, potentially leading to price competition and enhanced accessibility.
Key Takeaways
-
Primary Supplier: Melinta Therapeutics remains the sole manufacturer of Orbactiv, utilizing its own facilities and contract manufacturing organizations (CMOs) to meet demand.
-
Distribution Dynamics: Orbactiv’s distribution heavily relies on major pharmaceutical distributors and specialty pharmacies, with ongoing challenges related to manufacturing capacity and supply stability.
-
Supply Chain Risks: Manufacturing delays, financial instability of Melinta, and global supply chain disruptions affect Orbactiv availability, underscoring the need for diversified sourcing and strategic inventory management.
-
Future Outlook: No biosimilars or generics are currently available but may emerge as patents expire or manufacturing becomes more accessible. Technological advancements could further stabilize supply and reduce pricing.
-
Stakeholder Strategy: Healthcare providers should maintain vigilant inventory monitoring, establish reliable distribution channels, and stay informed about manufacturing updates or regulatory changes affecting Orbactiv supply.
FAQs
1. Who is the primary manufacturer of Orbactiv?
Melinta Therapeutics is currently the exclusive manufacturer of Orbactiv, producing the drug through its facilities and contracted third-party manufacturers.
2. Are there any approved generic versions of Orbactiv?
No, as of 2023, no generic or biosimilar versions of oritavancin have received regulatory approval, maintaining Melinta’s exclusive rights to produce and market Orbactiv.
3. What supply chain challenges could impact Orbactiv availability?
Manufacturing delays, financial instability of the primary manufacturer, complex synthesis requirements, and global supply disruptions are key challenges influencing supply stability.
4. How are distributors managing Orbactiv supply disruptions?
Distributors often rely on inventory management, alternative sourcing, and close communication with healthcare providers to mitigate shortages and ensure patient access.
5. Is there a possibility for biosimilar or generic Orbactiv in the future?
While patents currently protect Orbactiv, potential patent expirations and technological innovations could facilitate the development of biosimilars or generics, improving supply resilience and reducing costs.
Sources
[1] U.S. Food and Drug Administration (FDA). “Orbactiv (oritavancin) injection, for intravenous use.” 2014.
[2] Melinta Therapeutics. “Orbactiv (oritavancin) prescribing information.” 2022.
[3] MarketWatch. “Pharmaceutical supply chain disruptions and implications for antibiotics,” 2023.
[4] Reports from industry supply chain analyses, 2022–2023.
[5] Center for Drug Evaluation and Research (CDER). “Guidelines for biologic and biosimilar development,” 2021.
More… ↓
